Suppr超能文献

拉丁美洲带状疱疹流行病学:系统评价和荟萃分析。

Herpes zoster epidemiology in Latin America: A systematic review and meta-analysis.

机构信息

Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

GSK, Buenos Aires, Argentina.

出版信息

PLoS One. 2021 Aug 12;16(8):e0255877. doi: 10.1371/journal.pone.0255877. eCollection 2021.

Abstract

The epidemiology and burden of Herpes Zoster (HZ) are largely unknown, and there are no recent reviews summarizing the available evidence from the Latin America and Caribbean (LAC) region. We conducted a systematic review and meta-analysis to characterize the epidemiology and burden of HZ in LAC. Bibliographic databases and grey literature sources were consulted to find studies published (January 2000 -February 2020) with epidemiological endpoints: cumulative incidence and incidence density (HZ cases per 100,000 person-years), prevalence, case-fatality rates, HZ mortality, hospitalization rates, and rates of each HZ complication. Twenty-six studies were included with most studies coming from Brazil. No studies reported the incidence of HZ in the general population. In population at higher risk, the cumulative incidence ranged from 318-3,423 cases of HZ per 100,000 persons per year of follow-up. The incidence density was 6.4-36.5 cases per 1,000 person-years. Age was identified as a major risk factor towards HZ incidence which increase significantly in people >50 years of age. Hospitalization rates ranged from 3%-35.7%. The in-hospital HZ mortality rate ranged from 0%-36%. Overall, HZ mortality rates were found to be higher in females across all age groups and countries. The incidence of HZ complications (such as post-herpetic neuralgia, ophthalmic herpes zoster, and Ramsay Hunt syndrome) was higher in the immunosuppressed compared to the immunocompetent population. Acyclovir was the most frequently used therapy. Epidemiological data from Ministry of Health databases (Argentina, Brazil, Colombia, Chile y Mexico) and Institute for Health Metrics and Evaluation's Global Burden of Disease project reported stable rates of hospitalizations and deaths over the last 10 years. High-risk groups for HZ impose a considerable burden in LAC. They could benefit from directed healthcare initiatives, including adult immunization, to prevent HZ occurrence and its complications.

摘要

带状疱疹(HZ)的流行病学和负担在很大程度上尚不清楚,并且最近也没有综述总结来自拉丁美洲和加勒比地区(LAC)的现有证据。我们进行了一项系统评价和荟萃分析,以描述 LAC 地区 HZ 的流行病学和负担。检索了文献数据库和灰色文献来源,以找到发表于 2000 年 1 月至 2020 年 2 月期间具有流行病学终点(每 100,000 人年的累积发病率和发病率密度(HZ 病例数)、患病率、病死率、HZ 死亡率、住院率和每种 HZ 并发症的发生率)的研究。共纳入 26 项研究,其中大多数研究来自巴西。没有研究报告普通人群中 HZ 的发病率。在高危人群中,每年每 100,000 人随访中 HZ 的累积发病率范围为 318-3,423 例,发病率密度为 6.4-36.5 例/1,000 人年。年龄是 HZ 发病的主要危险因素,年龄超过 50 岁的人群发病率显著增加。住院率范围为 3%-35.7%。住院 HZ 死亡率范围为 0%-36%。总体而言,在所有年龄段和国家中,女性的 HZ 死亡率均高于男性。与免疫功能正常人群相比,免疫抑制人群 HZ 并发症(如带状疱疹后神经痛、眼疱疹性带状疱疹和 Ramsay Hunt 综合征)的发病率更高。阿昔洛韦是最常用的治疗药物。来自卫生部数据库(阿根廷、巴西、哥伦比亚、智利和墨西哥)和健康指标与评估研究所全球疾病负担项目的数据报告,过去 10 年来,住院和死亡人数的稳定率。HZ 的高危人群在 LAC 地区带来了相当大的负担。他们可以从定向医疗保健举措中受益,包括成人免疫接种,以预防 HZ 的发生及其并发症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/315c/8360515/e29d5a86ac91/pone.0255877.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验